https://www.selleckchem.com/pr....oducts/aticaprant.ht
5-year survival rates for all T1 BC patients were 84% (CSS) and 65% (OS). Delayed RC was associated with the lowest 5-year CSS (70%). After adjustment, gender did not impact treatment choice and CSS. The use of BCG as early treatment indicates low adherence to existing guidelines. Delayed RC was associated with low survival rates. An increased focus on the management of T1 patients is needed in Norway. The use of BCG as early treatment indicates low adherence to existing guidelines. Delayed RC was associated with low survival rates.